Precision BioSciences Inc
NASDAQ:DTIL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8.07
18.56
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DTIL stock under the Base Case scenario is 13.16 USD. Compared to the current market price of 8.08 USD, Precision BioSciences Inc is Undervalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Precision BioSciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DTIL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Precision BioSciences Inc
Balance Sheet Decomposition
Precision BioSciences Inc
Current Assets | 110.5m |
Cash & Short-Term Investments | 101.2m |
Receivables | 1.5m |
Other Current Assets | 7.8m |
Non-Current Assets | 42.7m |
Long-Term Investments | 3.2m |
PP&E | 11m |
Intangibles | 388k |
Other Non-Current Assets | 28.2m |
Current Liabilities | 12m |
Accounts Payable | 958k |
Accrued Liabilities | 8.2m |
Other Current Liabilities | 2.9m |
Non-Current Liabilities | 76.4m |
Long-Term Debt | 22.3m |
Other Non-Current Liabilities | 54.1m |
Earnings Waterfall
Precision BioSciences Inc
Revenue
|
75.1m
USD
|
Operating Expenses
|
-91.3m
USD
|
Operating Income
|
-16.2m
USD
|
Other Expenses
|
24.8m
USD
|
Net Income
|
8.6m
USD
|
Free Cash Flow Analysis
Precision BioSciences Inc
USD | |
Free Cash Flow | USD |
DTIL Profitability Score
Profitability Due Diligence
Precision BioSciences Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Precision BioSciences Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
DTIL Solvency Score
Solvency Due Diligence
Precision BioSciences Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Precision BioSciences Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DTIL Price Targets Summary
Precision BioSciences Inc
According to Wall Street analysts, the average 1-year price target for DTIL is 34.27 USD with a low forecast of 19.19 USD and a high forecast of 63 USD.
Dividends
Current shareholder yield for DTIL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DTIL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one DTIL stock under the Base Case scenario is 13.16 USD.
Compared to the current market price of 8.08 USD, Precision BioSciences Inc is Undervalued by 39%.